Contact UsCareers
Top bar
– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate -  Company to host virtual KOL event to review data today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc.